CIBC Asset Management
RXRX icon

CIBC Asset Management’s Recursion Pharmaceuticals RXRX Stock Holding History

CIBC Asset Management’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$48.7K Hold
15,865
– – ﹤0.01% 1348
2025
Q4 		$64.9K Buy
+15,865
New +$78.6K ﹤0.01% 1329

Other funds holding RXRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

CIBC Asset Management's RXRX Position: Q1 2026 in Review

CIBC Asset Management held its Recursion Pharmaceuticals (RXRX) position steady in Q1 2026 at 15,865 shares worth $48.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1348.

CIBC Asset Management first reported a position in RXRX in Q4 2025 and has held it in 2 quarters since. The position peaked at $64.9K in Q4 2025. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • CIBC Asset Management held 15,865 shares of Recursion Pharmaceuticals worth $48.7K as of Q1 2026.
  • CIBC Asset Management left its Recursion Pharmaceuticals share count unchanged in Q1 2026.
  • Recursion Pharmaceuticals made up ﹤0.01% of CIBC Asset Management's portfolio in Q1 2026, its #1348 holding.
  • CIBC Asset Management first reported a position in Recursion Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • CIBC Asset Management's Recursion Pharmaceuticals position peaked at $64.9K in Q4 2025.
  • 334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on CIBC Asset Management's 13F filing for Q1 2026, filed 12 May 2026.